Several studies demonstrated that anti-CCP2 and anti-CCP3 offer comparable performance characteristics in RA patients [7,8,9,10,11], whereas few reports showed that anti-CCP3 tests have better performance than anti-CCP2 assays [12,13]. This evidence concerns the gene AGBL2 and rheumatoid arthritis.